612 related articles for article (PubMed ID: 16219680)
1. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
[TBL] [Abstract][Full Text] [Related]
2. Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.
Gilch S; Nunziante M; Ertmer A; Schätzl HM
Vet Microbiol; 2007 Aug; 123(4):377-86. PubMed ID: 17493775
[TBL] [Abstract][Full Text] [Related]
3. Prion-protein-specific aptamer reduces PrPSc formation.
Proske D; Gilch S; Wopfner F; Schätzl HM; Winnacker EL; Famulok M
Chembiochem; 2002 Aug; 3(8):717-25. PubMed ID: 12203970
[TBL] [Abstract][Full Text] [Related]
4. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
[TBL] [Abstract][Full Text] [Related]
5. Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP.
Rambold AS; Miesbauer M; Olschewski D; Seidel R; Riemer C; Smale L; Brumm L; Levy M; Gazit E; Oesterhelt D; Baier M; Becker CF; Engelhard M; Winklhofer KF; Tatzelt J
J Neurochem; 2008 Oct; 107(1):218-29. PubMed ID: 18691383
[TBL] [Abstract][Full Text] [Related]
6. The highways and byways of prion protein trafficking.
Campana V; Sarnataro D; Zurzolo C
Trends Cell Biol; 2005 Feb; 15(2):102-11. PubMed ID: 15695097
[TBL] [Abstract][Full Text] [Related]
7. Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation.
Filesi I; Cardinale A; Mattei S; Biocca S
J Neurochem; 2007 Jun; 101(6):1516-26. PubMed ID: 17542810
[TBL] [Abstract][Full Text] [Related]
8. Misfolding of the prion protein at the plasma membrane induces endocytosis, intracellular retention and degradation.
Kiachopoulos S; Heske J; Tatzelt J; Winklhofer KF
Traffic; 2004 Jun; 5(6):426-36. PubMed ID: 15117317
[TBL] [Abstract][Full Text] [Related]
9. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
10. Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation.
Gilch S; Kehler C; Schätzl HM
J Mol Biol; 2007 Aug; 371(2):362-73. PubMed ID: 17574575
[TBL] [Abstract][Full Text] [Related]
11. The role of rafts in the fibrillization and aggregation of prions.
Pinheiro TJ
Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
[TBL] [Abstract][Full Text] [Related]
12. Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance.
Touil F; Pratt S; Mutter R; Chen B
J Pharm Biomed Anal; 2006 Mar; 40(4):822-32. PubMed ID: 16242887
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc.
Aguib Y; Gilch S; Krammer C; Ertmer A; Groschup MH; Schätzl HM
Mol Cell Neurosci; 2008 May; 38(1):98-109. PubMed ID: 18387818
[TBL] [Abstract][Full Text] [Related]
14. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity.
Vetrugno V; Cardinale A; Filesi I; Mattei S; Sy MS; Pocchiari M; Biocca S
Biochem Biophys Res Commun; 2005 Dec; 338(4):1791-7. PubMed ID: 16288721
[TBL] [Abstract][Full Text] [Related]
15. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein.
Liemann S; Glockshuber R
Biochemistry; 1999 Mar; 38(11):3258-67. PubMed ID: 10079068
[TBL] [Abstract][Full Text] [Related]
16. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease.
Gilch S; Winklhofer KF; Groschup MH; Nunziante M; Lucassen R; Spielhaupter C; Muranyi W; Riesner D; Tatzelt J; Schätzl HM
EMBO J; 2001 Aug; 20(15):3957-66. PubMed ID: 11483499
[TBL] [Abstract][Full Text] [Related]
17. Towards cellular receptors for prions.
Lee KS; Linden R; Prado MA; Brentani RR; Martins VR
Rev Med Virol; 2003; 13(6):399-408. PubMed ID: 14625887
[TBL] [Abstract][Full Text] [Related]
18. Mapping of possible prion protein self-interaction domains using peptide arrays.
Rigter A; Langeveld JP; Timmers-Parohi D; Jacobs JG; Moonen PL; Bossers A
BMC Biochem; 2007 Apr; 8():6. PubMed ID: 17430579
[TBL] [Abstract][Full Text] [Related]
19. The scrapie prion protein is present in flotillin-1-positive vesicles in central- but not peripheral-derived neuronal cell lines.
Pimpinelli F; Lehmann S; Maridonneau-Parini I
Eur J Neurosci; 2005 Apr; 21(8):2063-72. PubMed ID: 15869502
[TBL] [Abstract][Full Text] [Related]
20. The retention of prion protein in the endoplasmic reticulum prevents N2A cells from proteasome inhibition-induced cytotoxicity.
Fang S; Wang R; Liu H; Zhuang W; Wang Z; Zhang J; Pei L; Liu Y; Su Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):500-507. PubMed ID: 28669732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
